| Literature DB >> 27378951 |
Mylène Laforest1, Stéphane Bouchard2, Jessie Bossé3, Olivier Mesly4.
Abstract
Obsessive-compulsive disorder (OCD) is characterized by the presence of distressing, recurrent and intrusive thoughts, impulses, or doubts as well as behavioral or mental rituals. OCD has various subtypes, including the fear of contamination in which individuals fear bacteria, germs, disease, or bodily secretions, and engage in clinically significant cleaning and avoidance rituals. Cognitive-behavioral therapy (CBT) is an effective treatment for OCD and involves, among other therapeutic strategies, exposing patients to feared stimuli while preventing them to engage in compulsive behaviors. In recent years, virtual reality (VR) has shown the potential of in virtuo exposure with people suffering from anxiety disorders and OCD. The objective of this pilot study is to examine the effectiveness of a CBT program where exposure in conducted in virtuo. Three adults suffering from OCD with a dominant subtype of contamination were enrolled in a single-case design with multiple baselines across participants. The presence and intensity of obsessions and compulsions were assessed daily during baselines of 3-, 4-, or 5-week, and a 12-session treatment. Follow-up information was gathered after 4 and 8 months. Treatment outcome is assessed with visual inspection of the graphs and ARMA time-series analyses. Clinical information, self-reports, and details of the treatment are provided for each patient. Statistical analyses for the time-series data revealed a statistically significant improvement in all three participants, but global improvement is considered positive for only two. This study innovates in proving preliminary support for the usefulness of VR in the CBT of OCD with contamination features.Entities:
Keywords: CBT; exposure; obsessive–compulsive disorder; response prevention; virtual reality
Year: 2016 PMID: 27378951 PMCID: PMC4904031 DOI: 10.3389/fpsyt.2016.00099
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Screenshots of the virtual environment used for exposure and response prevention in a “contaminated” public toilet.
Figure 2Presence of obsessions on a daily basis for the three participants. The first (solid) vertical line represents when CBT was introduced. The second and third (dashed) vertical lines represent when in virtuo exposure was conducted.
Figure 5Intensity of compulsions on a daily basis for the three participants. The first (solid) vertical line represents when CBT was introduced. The second and third (dashed) vertical lines represent when in virtuo exposure was conducted.
Results for measures of anxiety and daily functioning completed pre- and posttreatments as well as at the fourth and eighth month follow-ups.
| Participant 1 | Participant 2 | Participant 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Measures | Pre | Post | Follow-up 4 months | Follow-up 8 months | Pre | Post | Follow-up 4 months | Follow-up 8 months | Pre | Post | Follow-up 4 months | Follow-up 8 months |
| YBOCS | 22 | 14 | 16 | 21 | 31 | 14 | 11 | 11 | 30 | 21 | 23 | 27 |
| TAI-Y2 | 32 | 31 | 29 | 28 | 61 | 60 | 46 | 46 | 56 | 59 | 54 | 64 |
| EALF | 3.5 | 2.3 | 2.3 | 2.3 | 5.3 | 3.0 | 1.3 | 1.5 | 7.8 | 5.5 | 7.5 | 8.3 |
YBOCS, Yale–Brown Obsessive–Compulsive Scale; TAI-Y2, Trait-Anxiety Inventory (Form Y2 of the STAI); EALF, evaluation of actual life functioning.
Results for time-series analyses performed on the presence and the intensity of obsessions and compulsions in the three participants.
| Variable participant | Final ARMA model | Jung-box | Intervention parameter ( | Significant change occurring at session number |
|---|---|---|---|---|
| P1 | AR-1 | 19.75 | −3.13*** | Session 7 |
| P2 | AR-1 | 23.54 | −3.42*** | Session 1 |
| P3 | AR-1 | 16.63 | −4.14*** | Session 10 |
| P1 | AR-1 | 25.81 | −2.97** | Session 6 |
| P2 | AR-1 | 21.16 | −5.80*** | Session 9 |
| P3 | AR-2 | 9.55 | −4.56*** | Session 8 |
| P1 | AR-1 | 21.49 | −4.86*** | Session 9 |
| P2 | AR-1 | 23.15 | −2.75*** | Session 1 |
| P3 | AR-1 | 20.72 | −3.53*** | Session 9 |
| P1 | AR-2 | 18.62 | −4.28*** | Session 8 |
| P2 | AR-1 | 9.50 | −7.09*** | Session 10 |
| P3 | AR-1 | 9.46 | −3.14*** | Session 8 |
AR, autoregression model; MA, moving average model.
**.